| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S11239-011-0578-5 |
| P698 | PubMed publication ID | 21404067 |
| P2093 | author name string | Richard C Becker | |
| Rebecca S Woodruff | |||
| Bruce Sullenger | |||
| P2860 | cites work | Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R) | Q24313325 |
| Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor | Q24320005 | ||
| Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation | Q24336585 | ||
| Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis | Q24602015 | ||
| Defective thrombus formation in mice lacking coagulation factor XII | Q24646366 | ||
| Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa | Q24649797 | ||
| Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo | Q24655664 | ||
| Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants | Q27643376 | ||
| The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface | Q28115496 | ||
| Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII | Q28115845 | ||
| Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1 | Q28201194 | ||
| Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice | Q28218191 | ||
| Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2 | Q28266203 | ||
| The molecular basis of blood coagulation | Q28294854 | ||
| Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor | Q28299224 | ||
| Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor) | Q28306231 | ||
| Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis | Q28508572 | ||
| Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis | Q28510902 | ||
| Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential | Q28628884 | ||
| Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes | Q28628970 | ||
| Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains | Q28630112 | ||
| Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces | Q28630174 | ||
| Binding of coagulation factor XI to washed human platelets | Q28630716 | ||
| Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII | Q28631351 | ||
| Thrombin activates factor XI on activated platelets in the absence of factor XII | Q28631554 | ||
| A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo | Q28748458 | ||
| Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. | Q30362649 | ||
| Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation | Q30479254 | ||
| Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades | Q33221597 | ||
| Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis | Q33305420 | ||
| Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential | Q33649297 | ||
| Activation of the plasma kallikrein/kinin system on cells: a revised hypothesis. | Q33799967 | ||
| Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis | Q33931725 | ||
| Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator | Q34112923 | ||
| Early atherosclerosis exhibits an enhanced procoagulant state. | Q34130566 | ||
| Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein | Q34186280 | ||
| Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa | Q34193071 | ||
| WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | Q34257361 | ||
| Polyphosphate modulates blood coagulation and fibrinolysis. | Q34304738 | ||
| Activation of blood clotting factors by microbial proteinases | Q34323403 | ||
| Assembly of contact-phase factors on the surface of the human neutrophil membrane | Q34329853 | ||
| The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature | Q34340628 | ||
| Polyphosphate exerts differential effects on blood clotting, depending on polymer size. | Q34360392 | ||
| Factor XI activation in a revised model of blood coagulation | Q34500136 | ||
| Platelet polyphosphate: an endogenous activator of coagulation factor XII | Q34599754 | ||
| The plasma kallikrein-kinin system counterbalances the renin-angiotensin system | Q34603054 | ||
| Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner | Q35200296 | ||
| Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. | Q35208713 | ||
| A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma | Q35282990 | ||
| Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin | Q35849803 | ||
| Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation | Q36022988 | ||
| Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. | Q36055525 | ||
| Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein | Q36272715 | ||
| Activation of the classical pathway of complement by Hageman factor fragment | Q36344568 | ||
| Cross-talk of the renin-angiotensin and kallikrein-kinin systems | Q36404466 | ||
| A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets | Q36867848 | ||
| Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI | Q37071138 | ||
| Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation | Q37078887 | ||
| Evolution of the contact phase of vertebrate blood coagulation | Q37153442 | ||
| Factor XI contributes to thrombin generation in the absence of factor XII | Q37271059 | ||
| Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII) | Q37346121 | ||
| Evidence of a U-shaped association between factor XII activity and overall survival. | Q51759263 | ||
| Plasma levels of bradykinin are suppressed in factor XII-deficient mice. | Q51802842 | ||
| Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. | Q52572099 | ||
| Kinetics of activation and autoactivation of human factor XII. | Q52696407 | ||
| Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. | Q53648798 | ||
| Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. | Q53670507 | ||
| Activation of blood clotting factors by microbial proteinases | Q56706175 | ||
| C1 inhibitor, a multi-functional serine protease inhibitor | Q56772868 | ||
| Kallikrein-Kinin System in Neovascularization | Q56963291 | ||
| Identification of a Binding Site for Glycoprotein Ibα in the Apple 3 Domain of Factor XI | Q57372279 | ||
| Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk | Q58956899 | ||
| Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade | Q62482835 | ||
| Activation of bovine factor VII by hageman factor fragments | Q67013242 | ||
| Synthesis of peptides of arginine chloromethyl ketone. Selective inactivation of human plasma kallikrein | Q67427237 | ||
| The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism | Q67939877 | ||
| Purified plasma factor XIIa aggregates human neutrophils and causes degranulation | Q68798232 | ||
| Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface | Q68799818 | ||
| Extrinsic pathway proteolytic activity | Q70511905 | ||
| Autoactivatability of human Hageman factor (factor XII) | Q71154185 | ||
| Hageman factor (factor XII) deficiency in marine mammals | Q71342285 | ||
| Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein | Q71516712 | ||
| Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator | Q71585817 | ||
| Identification of a factor IX binding site on the third apple domain of activated factor XI | Q71763368 | ||
| Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis | Q71789536 | ||
| The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein | Q71939378 | ||
| Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin | Q73145818 | ||
| Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates | Q73256328 | ||
| Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation | Q73307874 | ||
| High levels of coagulation factor XI as a risk factor for venous thrombosis | Q73520981 | ||
| Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation | Q73763204 | ||
| Defective binding of factor XI-N248 to activated human platelets | Q74064343 | ||
| FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse | Q74091024 | ||
| The contact system: a proinflammatory pathway with antithrombotic activity | Q74310264 | ||
| Factor XII does not initiate prekallikrein activation on endothelial cells | Q74823530 | ||
| Interaction of high molecular weight kininogen binding proteins on endothelial cells | Q75202183 | ||
| Molecular genetics of C1 inhibitor | Q77428565 | ||
| Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation | Q77647784 | ||
| Fibrinolytic properties of activated FXII | Q78197350 | ||
| Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events | Q80034677 | ||
| Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice | Q80232996 | ||
| Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats | Q80540408 | ||
| Reduced incidence of ischemic stroke in patients with severe factor XI deficiency | Q80681812 | ||
| Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors | Q81223954 | ||
| Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression | Q82152526 | ||
| Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces | Q84589400 | ||
| Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). | Q37374500 | ||
| Step-by-step evolution of vertebrate blood coagulation | Q37576876 | ||
| Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII) | Q37584724 | ||
| Inhibition of factor XIa as a new approach to anticoagulation | Q37688730 | ||
| Molecular characterization of FXI deficiency | Q37716295 | ||
| COU254, a specific 3-carboxamide-coumarin inhibitor of coagulation factor XII, does not protect mice from acute ischemic stroke | Q39392693 | ||
| Role of the contact system in fibrinolysis | Q39594111 | ||
| Anaphylatoxins: C3a and C5a | Q39773298 | ||
| Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor | Q39796241 | ||
| Activation of the contact-phase system on bacterial surfaces--a clue to serious complications in infectious diseases | Q40640988 | ||
| The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule | Q40982763 | ||
| Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma | Q41814564 | ||
| Crystal structure of the factor XI zymogen reveals a pathway for transactivation | Q42152415 | ||
| Orphan receptor hepatocyte nuclear factor-4 antagonizes estrogen receptor alpha-mediated induction of human coagulation factor XII gene | Q42463195 | ||
| Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. | Q42921025 | ||
| Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding | Q43121714 | ||
| Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis | Q43188443 | ||
| Homozygosity for the C-->T polymorphism at nucleotide 46 in the 5' untranslated region of the factor XII gene protects from development of acute coronary syndrome | Q43695448 | ||
| Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study | Q44123484 | ||
| Infestin, a thrombin inhibitor presents in Triatoma infestans midgut, a Chagas' disease vector: gene cloning, expression and characterization of the inhibitor. | Q44126331 | ||
| John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study | Q44652745 | ||
| Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies | Q45205740 | ||
| Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. | Q45865011 | ||
| Real-time quantitative PCR analysis of factor XI mRNA variants in human platelets | Q45878459 | ||
| Blood coagulation in hemophilia A and hemophilia C. | Q45887648 | ||
| Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. | Q45980975 | ||
| Dual role of collagen in factor XII-dependent thrombus formation | Q46048146 | ||
| Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease | Q46695250 | ||
| Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. | Q46959710 | ||
| Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor | Q46988574 | ||
| Surface-independent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement. | Q47856260 | ||
| Enhanced cortical reperfusion protects coagulation factor XII-deficient mice from ischemic stroke as revealed by high-field MRI. | Q48390549 | ||
| Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice | Q48939342 | ||
| Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency | Q50324469 | ||
| Inherited factor XI deficiency confers no protection against acute myocardial infarction. | Q50722827 | ||
| P433 | issue | 1 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 9-20 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | The many faces of the contact pathway and their role in thrombosis | |
| P478 | volume | 32 |
| Q36093372 | Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization |
| Q42551076 | Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay |
| Q57169764 | Establishing a protocol for thromboelastography in sea turtles |
| Q37626463 | Evidence for factor IX-independent roles for factor XIa in blood coagulation. |
| Q39886396 | FXIIa inhibitor rHA-Infestin-4: Safe thromboprotection in experimental venous, arterial and foreign surface-induced thrombosis |
| Q27024190 | Factor XI and contact activation as targets for antithrombotic therapy |
| Q37636983 | Factor XII inhibition reduces thrombus formation in a primate thrombosis model |
| Q35005516 | Genetic variants of coagulation factor XI show association with ischemic stroke up to 70 years of age. |
| Q27684478 | Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody |
| Q47316465 | Kallikrein Cleaves C3 and Activates Complement. |
| Q40277454 | Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome |
| Q38364069 | Microparticle analysis in disorders of hemostasis and thrombosis |
| Q35193770 | Murine models in the evaluation of heparan sulfate-based anticoagulants |
| Q38014345 | Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. |
| Q42581851 | Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation |
| Q41857889 | Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model. |
| Q27333692 | Spatiotemporal characterization of a fibrin clot using quantitative phase imaging |
| Q35905607 | The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats |
Search more.